FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Glaxo bonds bring whopping $9B

GlaxoSmithKline went hat in hand to the bond markets and came back with a record $9 billion. Intending to sell $6 billion in corporate bonds, GSK added $3 billion more as investors hungry for non-financial corporate issues snapped up the offerings.

GSK plans to use the proceeds for its big share buy-back plan. That plan is designed to strengthen GSK stock at a time when the entire pharma sector is suffering on the equity markets.

- read the story in the Financial Times

ALSO: In Vivo is reporting that GlaxoSmithKline plans to set aside up to $500 million for a new venture fund that will support its internal R&D work as well as fund start-ups created from de-prioritized assets. GSK report

Related Articles:
Best and Worst Pharma stocks of 2007
Big Biotech emerges as a shelter in economic storm
Big Biotech's Stock Report

More stories about Pharma Stocks   GlaxoSmithKline  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 8 + 15?
To combat spam, please solve the math question above.